Attached files
| file | filename |
|---|---|
| EX-31.2 - EXHIBIT 31.2 - Avalo Therapeutics, Inc. | cercex-312.htm |
| EX-32.1 - EXHIBIT 32.1 - Avalo Therapeutics, Inc. | cercex-321.htm |
| EX-31.1 - EXHIBIT 31.1 - Avalo Therapeutics, Inc. | cercex-311.htm |
| EX-21.1 - EXHIBIT 21.1 - Avalo Therapeutics, Inc. | cercex-211.htm |
| 10-K - 10-K - Avalo Therapeutics, Inc. | cerc10-k20161231.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm |
We consent to the incorporation by reference in the following Registration Statements: (1) Registration Form (Form S-8 No. 333-207949) pertaining to the 2015 Omnibus Incentive Compensation Plan, (2) Registration Statement on (Form S-8 No. 333-211490) pertaining to the 2016 Equity Incentive Plan (3) Registration Statement on (Form S-8 No. 333-211491) pertaining to the 2016 Employee Stock Purchase Plan (4) Registration Statement on (Form S-1 No. 333-211491) as filed on September 16, 2016 (5) Registration Statement on (Form S-3 No. 333-214507) as filed on November 8, 2016 of our report dated March 14, 2017, with respect to the financial statements of Cerecor Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2016. |
/s/ Ernst & Young LLP
Baltimore, Maryland
March 14, 2017